Circulating tumor DNA as biomarker for perihilar cholangiocarcinoma

Circulating tumor DNA as a biomarker in perihilar cholangiocarcinoma: a feasibility study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27478

Enrollment

Registered

2016-08-31

Start date

2016-09-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perihilar cholangiocarcinoma/ Perihilair cholangiocarcinoom Klatskin-tumor Biomarker Circulating tumor DNA /Circulerend tumor DNA (ctDNA)

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: -Patients older than 18 years. -Undergoing explorative laparotomy, diagnostic laparoscopy or percutaneous biopsy. -Able to understand the information given and provide written informed consent.

Exclusion criteria

Exclusion criteria: -Patients 18 years or younger. -Unfit for laparotomy/ diagnostic laparoscopy/ biopsies or blood analyses in palliative chemotherapy studies. -HIV/AIDS/hepatitis C in medical history. -Not able to give informed consent (language, intellectual capacities, etc.).

Design outcomes

Primary

Measure	Time frame
The aim of this study is to investigate if ctDNA is detectable in the blood of patients with pathologically proven PHC.	—

Secondary

Measure	Time frame
We will perform mutation analyses on PHC samples to contribute to the literature on mutational profiles of PHC paving the way for implementation in clinical use.	—

Contacts

Public ContactEline Soer

Academic Medical Center (AMC), Amsterdam

e.c.soer@amc.uva.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)